We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current CSTL market cap is 771.04M. The company's latest EPS is USD -2.0518 and P/E is -13.41.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 61.49M | 66.12M | 72.97M | 87M | 85.78M |
Operating Income | -9.64M | -5.66M | -5.47M | 5.01M | 5.08M |
Net Income | -6.91M | -2.58M | -2.53M | 8.92M | 2.27M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 51.87M | 64.53M | 94.09M | 155.33M | 219.79M |
Operating Income | 7.33M | -6.54M | -40.08M | -72.86M | -67.98M |
Net Income | 2.99M | -10.28M | -31.29M | -67.14M | -57.47M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 436.02M | 453.34M | 458.51M | 487.31M | 514.57M |
Total Liabilities | 50.24M | 62.07M | 56.05M | 63.42M | 73.51M |
Total Equity | 385.78M | 391.27M | 402.46M | 423.89M | 441.06M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 119.75M | 439.33M | 462.57M | 447.33M | 453.34M |
Total Liabilities | 34.63M | 23.64M | 50.83M | 48.18M | 62.07M |
Total Equity | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -24.21M | -5.63M | -6.84M | 17.16M | 40.5M |
Investing | -8.51M | -16.18M | -19.7M | -41.12M | -55.91M |
Financing | 999k | -2.3M | 10.64M | 10.69M | 11.52M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 7.02M | 9.87M | -18.98M | -41.66M | -5.63M |
Investing | -937k | -4.75M | -66.66M | -166.55M | -16.18M |
Financing | 88.29M | 305.89M | 5.42M | 1.52M | -2.3M |
Market Cap | 771.04M |
Price to Earnings Ratio | -13.41 |
Price to Sales Ratio | 3.51 |
Price to Cash Ratio | 7.8 |
Price to Book Ratio | 1.97 |
Dividend Yield | - |
Shares Outstanding | 28.01M |
Average Volume (1 week) | 262.06k |
Average Volume (1 Month) | 307.43k |
52 Week Change | 31.35% |
52 Week High | 35.6973 |
52 Week Low | 16.965 |
Spread (Intraday) | 17.5 (38.89%) |
Company Name | Castle Biosciences Inc |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://www.castlebiosciences.com |
Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions